Company intelligence / Profile preview

Aptissen

Plan-les-Ouates, Geneva, Switzerlandaptissen.com ↗

Ownership: Private
Employees: ~55
Development stage: Commercial

Overview

Aptissen has developed and commercialized biopolymer-based injectable products for joint health. Its flagship product, Synolis VA—a combination of hyaluronic acid and sorbitol—has demonstrated rapid mobility recovery and long-lasting pain relief with an excellent safety profile. The company distributes its products in over 90 countries worldwide.

Therapeutic areas: Rheumatology
Modalities: BiologicBiopolymer-based medical device
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

Synolis

Commercial

Indications: Osteoarthritis, Musculoskeletal pain

1 more asset in the full pipeline.

Request access →

Partnerships

Pharmaceutical/biotech/medtech partners for distribution and development

Beyond the preview

Go deeper on Aptissen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aptissen.

Explore the full profile